Jeffrey I. Weitz
0000-0002-1092-7550
Publication & Citation Trends
Publications
0 total
In the ED, the Wells score plus age-adjusted D-dimer score ruled out DVT with a failure rate ≤0.8% at 3 mo
Cited by 0
Semantic Scholar
Oral Factor XIa Inhibitor Milvexian After a Recent Acute Coronary Syndrome: Rationale and Design of the Phase 3 (Librexia ACS). OA
Cited by 7
Semantic Scholar
Factor XI inhibitors for the prevention and treatment of venous and arterial thromboembolism
Cited by 24
Semantic Scholar
Current Gaps in the Provision of Safe and Effective Anticoagulation in Atrial Fibrillation and the Potential for Factor XI-Directed Therapeutics OA
Cited by 2
Semantic Scholar
XI before X: The Promise of Factor XI Inhibitors OA
Cited by 0
Semantic Scholar
Milvexian vs apixaban for stroke prevention in atrial fibrillation: The LIBREXIA atrial fibrillation trial rationale and design. OA
Cited by 26
Semantic Scholar
Anticoagulation with osocimab in patients with kidney failure undergoing hemodialysis: a randomized phase 2 trial OA
Cited by 29
Semantic Scholar
International Clinical Practice Guideline Recommendations for Acute Pulmonary Embolism: Harmony, Dissonance, and Silence.
Cited by 46
Semantic Scholar
Global Health Burden of Venous Thromboembolism
Cited by 50
Semantic Scholar
Research Topics
Venous Thromboembolism Diagnosis and Management
(396)
Atrial Fibrillation Management and Outcomes
(327)
Blood Coagulation and Thrombosis Mechanisms
(206)
Antiplatelet Therapy and Cardiovascular Diseases
(121)
Acute Myocardial Infarction Research
(75)
Affiliations
Linköping University
Northwestern University
University of Veterinary Sciences Brno
University of North Carolina at Chapel Hill
Scripps Research Institute